An ontogenetic switch drives the positive and negative selection of B cells
CORNALL R. et al, (2020), PNAS
Technological advances and computational approaches for alternative splicing analysis in single cells.
Wen WX. et al, (2020), Comput Struct Biotechnol J, 18, 332 - 343
The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib.
O'Sullivan JM. et al, (2019), Blood, 134, 2107 - 2111
Cell-intrinsic depletion of Aml1-ETO-expressing pre-leukemic hematopoietic stem cells by K-Ras activating mutation.
Di Genua C. et al, (2019), Haematologica, 104, 2215 - 2224
Low-dose methotrexate: potential clinical impact on haematological and constitutional symptoms in myeloproliferative neoplasms.
Francis S. et al, (2019), Br J Haematol, 187, e69 - e72
Discovery of a CD10-negative B-progenitor in human fetal life identifies unique ontogeny-related developmental programs.
O'Byrne S. et al, (2019), Blood, 134, 1059 - 1071
Improving the diagnosis and classification of Ph-negative myeloproliferative neoplasms through deep phenotyping
Sirinukunwattana K. et al, (2019), bioRxiv
Transcriptomic profiling of the myeloma bone-lining niche reveals BMP signalling inhibition to improve bone disease
GOODING S. et al, (2019), Nature Communications
Germline selection shapes human mitochondrial DNA diversity.
Wei W. et al, (2019), Science (New York, N.Y.), 364
Single-cell approaches reveal novel cellular pathways for megakaryocyte and erythroid differentiation.
Psaila B. and Mead AJ., (2019), Blood, 133, 1427 - 1435
Single-cell assessment of transcriptome alterations induced by Scriptaid in early differentiated human haematopoietic progenitors during ex vivo expansion
ROBERTS IRENE. et al, (2019), Scientific Reports
Unravelling Intratumoral Heterogeneity through High-Sensitivity Single-Cell Mutational Analysis and Parallel RNA Sequencing.
Rodriguez-Meira A. et al, (2019), Mol Cell, 73, 1292 - 1305.e8
UK results from the myeloproliferative neoplasms (MPN) landmark survey on the symptom, emotional and economic burden of MPN.
Harrison C. et al, (2019), British journal of haematology
A physician survey on the application of the British Society for Haematology guidelines for the diagnosis and management of myelofibrosis in the UK
Harrison C. et al, (2019), BRITISH JOURNAL OF HAEMATOLOGY, 185, 66 - 67
A Retrospective Real World Evidence Study To Review The Current Treatment Pathways for Myelofibrosis From Across The United Kingdom (The REALISM UK Study)
Mead A. et al, (2019), BRITISH JOURNAL OF HAEMATOLOGY, 185, 8 - 9
The UK Myeloproliferative Neoplasm Registry for Myelofibrosis (UK-MPN-MF registry)
Butt NM. et al, (2019), BRITISH JOURNAL OF HAEMATOLOGY, 185, 54 - 55
Whole genome sequencing for the investigation of rare anaemias: Challenges and real-world outcomes
Brierley C. et al, (2019), BRITISH JOURNAL OF HAEMATOLOGY, 185, 115 - 116
Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study.
Gupta V. et al, (2019), Biol Blood Marrow Transplant, 25, 256 - 264
A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis: A British Society for Haematology Guideline.
McMullin MFF. et al, (2019), British journal of haematology, 184, 161 - 175
Heterogeneity in myeloproliferative neoplasms: Causes and consequences.
O'Sullivan J. and Mead AJ., (2019), Adv Biol Regul, 71, 55 - 68